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Commentary
After observations of frank toxicity in the 
mass poisoning episodes in Japan in the 
1950s and in Iraq in the 1970s (World 
Health Organization 1990), there was a slow 
realization that lower levels of exposure to 
methylmercury (MeHg) were also capable 
of causing more subtle forms of toxicity not 
readily apparent on an individual, clinical 
level. Population-based studies have detected 
neurodevelopmental deficits [National 
Research Council (NRC) 2000] and prob-
able cardiovascular effects, particularly an 
increased risk of myocardial infarction 
(Stern 2005a). Fish consumption advisories 
for MeHg have been developed based on 
this understanding and have generally been 
derived from the reference dose (RfD) for 
MeHg that addresses neurodevelopmental 
risk [U.S. Environmental Protection (EPA) 
2001]. After realizing that MeHg risk assess-
ment should be broadened to encompass 
these more subtle forms of toxicity, research-
ers also recognized that beneficial aspects of 
fish consumption should be considered when 
assessing MeHg risk. Although fish provide 
several beneficial constituents, much of the 
research on the benefits of fish consumption 
has focused on polyunsaturated fatty acids 
(PUFAs) (also referred to as omega-3 fatty 
acids and n-3 fatty acids), particularly docosa-
hexaenoic acid (DHA) and eicosapentaenoic 
acid (EPA), which are typical and abundant 
PUFAs. PUFAs appear to be associated with 
enhancement of neurodevelopmental func-
tion when exposure occurs during gestation 
and possibly lactation (Cansev et al. 2009; 
Levant et al. 2010; Mozaffarian and Rimm 
2006; Ryan et al. 2010) and with cardio-
vascular health in adulthood (Mozaffarian 
et al. 2010; Mozaffarian and Rimm 2006; 
Roth and Harris 2010; Siddiqui et al. 2009). 
MeHg produces adverse effects on these 
same general end points—neurodevelopment 
(NRC 2000) and cardiovascular health (Stern 
2005a; Virtanen et al. 2007). Thus, balancing 
the risk of MeHg and the benefit of PUFA 
from fish consumption can be seen, at least in 
part, as the weighing of competing influences.
In proposing an approach for balancing 
MeHg and PUFA benefit in the crafting of 
fish consumption advisories, we focus here 
on neurodevelopmental risks and benefits 
because that is the end point addressed by the 
current U.S. EPA RfD (2001). However, the 
same considerations would apply in balanc-
ing cardiovascular risks and benefits. It is also 
important to note that for the purposes of this 
discussion, we are focusing only on MeHg 
risk and omega-3 benefit. There are other 
potential contaminants in fish for which the 
balancing of risks and benefits is not neces-
sarily addressed by the same considerations 
that apply to MeHg and PUFAs. Likewise, 
there are potentially other beneficial constitu-
ents of fish for which data on benefits are 
not necessarily confounded by co-occurring 
contaminants. Because much of the practi-
cal discussion about balancing MeHg risk 
against the benefits of fish consumption has 
focused on PUFA benefits (Cohen et al. 
2005; Guallar et al. 2002; Mozaffarian and 
Rimm 2006), as have proposals for construct-
ing fish consumption advisories (Ginsberg 
and Toal 2009; Gochfeld and Burger 2005), 
we have likewise chosen to focus on these two 
parameters. However, the following discus-
sion should not be taken to imply that these 
are the only sources of risk and benefit in fish.
The Problem
Given that MeHg and PUFA operate largely 
in different directions on the same end points, 
the analysis of data on risk and/or on the 
bene  fit of fish consumption to derive practical 
fish consumption advisories is not straight-
forward. This is because in studies of fish-
consuming populations, data on the adverse 
effects of MeHg will be confounded by the 
simultaneously competing PUFA benefits, and 
data on PUFA benefits will be confounded by 
competing MeHg risks. In contrast to clas-
sic statistical confounding in which two or 
more variables affect the outcome in the same 
direction, this type of confounding with two 
variables affecting the outcome in opposite 
directions has been referred to as negative 
confounding (Choi et al. 2008). Because the 
major source (and for most populations, the 
only source) of MeHg exposure is fish con-
sumption and because all fish contain at least 
some PUFAs, this confounding means that 
studies of fish consumers will underestimate 
the underlying risk of MeHg and simultane-
ously underestimate the underlying benefit of 
PUFAs (generically represented in Figure 1). 
For convenience, true and observed bene-
fit and true and observed risk are shown on 
the same graph in Figure 1, but this should 
not be taken to imply that observed risk and 
observed benefit occur simultaneously for the 
same outcome. Figure 2 presents an empirical 
example of this from Guallar et al. (2002). 
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Although Figure 2 is derived from myocardial 
risk–benefit data, the principle it illustrates 
applies equally to neurodevelopmental risk–
benefit analysis.
How Can We Overcome This 
Problem to Provide Appropriate 
Fish Consumption Advice?
Clearly, some combinations of MeHg and 
omega-3s in fish lend themselves to obvious 
consumption advice. Fish with characteristi-
cally high levels of PUFAs and low MeHg, 
such as anchovies, sardines, herring, and 
salmon, will pose net benefits. Conversely, fish 
with characteristically high levels of MeHg and 
low levels of PUFAs, for example, swordfish 
and shark, will pose a net risk. The difficulty 
arises when we think about how to craft advi-
sories for fish with intermediate levels of MeHg 
and PUFAs, including tuna, snapper, bluefish, 
sea bass, freshwater bass, pike, and walleye.
Several studies have regressed data on 
health outcomes against fish consumption as a 
whole rather than against PUFAs and MeHg 
(Daniels et al. 2004; Lederman et al. 2008; 
Oken et al. 2008a, 2008b). There are two 
reasons why such an approach should not be 
used to construct risk–benefit fish consump-
tion advisories. The first is that in almost any 
fish-consuming population, there will be a 
variety of patterns of fish consumption. Each 
pattern will contribute different combinations 
of MeHg and PUFA intake, but regression 
of outcome against fish consumption inher-
ently assumes that all consumers eat the same 
average diet. The second reason is even if it is 
assumed that a single fish diet is representative 
of a given population, the risk–benefit balance 
derived from that population can be applied 
to a different population only if it is assumed 
that the second population eats the same fish 
diet with the same MeHg–PUFA balance; this 
is by no means an obvious assumption.
Another possibility is to obtain risk infor-
mation from one study that quantifies MeHg 
exposure but not PUFA intake and benefit 
information from a different study that pro-
vides data on PUFA intake but not MeHg 
intake data. Under such a scheme, regression 
coefficients, BMDLs (benchmark dose–low), 
or plateau values in a dose–response curve for 
adverse effects and benefits could be compared. 
The problem with this approach is that, as rep-
resented in Figure 1, PUFA intake–benefit data 
derived from studies of fish-consuming popula-
tions will be at least partly obscured by MeHg 
effects on the same end point. Similarly, MeHg 
intake–risk data will be obscured by PUFA 
effects. Even if the PUFA benefit data are 
derived from studies in which PUFAs are sup-
plied by dietary supplementation and not from 
fish, it is difficult to imagine a useful source 
of MeHg intake–risk data that is not derived 
from fish consumption with attendant PUFA 
intake. Thus, even if PUFA-benefit data can be 
obtained free of MeHg confounding, uncon-
founded MeHg risk data are not obtainable.
Instead, risk data and benefit data are 
needed that are derived from the same study in 
the same population and not obscured by each 
other. We can think of these unconfounded 
estimates as naked risk and benefit data.
Obtaining and Using 
Unconfounded Risk and 
Benefit Information
The data necessary to generate unconfounded 
risk and benefit information can be derived 
from well-designed population-based epide-
miological studies that generate MeHg and 
PUFA intake estimates by subject. Intake can 
be derived from accurate dietary survey data or 
from MeHg and PUFA biomarker measure-
ments from which intake can be estimated by 
applying pharmacokinetic models. Models are 
available that relate MeHg biomarkers (hair 
and blood) to intake (Shipp et al 2000; Stern 
2005b). Relevant pharmacokinetic data are 
available for PUFAs (Masson et al. 2007; Rusca 
et al. 2009), but it does not appear that models 
specifically relating PUFA intake to biomarker 
concentration have been published to date. 
Population-based multiple regression (or struc-
tural equation) models of appropriate outcomes 
[e.g., intelligence quotient (IQ)] can then be 
constructed and are regressed against the inde-
pendent variables of PUFA and MeHg intake. 
In multiple regression, the coefficient (β) of 
each independent variable reflects the slope of 
the response to each increment of that vari-
able when the slopes of all other independent 
variables are held constant—when controlling 
for or adjusting for the other independent vari-
ables. Therefore, if we have a regression model 
for a gestational neurodevelopmental outcome 
such as IQ with both maternal MeHg intake 
and maternal PUFA intake as independent 
variables, the β for each reflects the uncon-
founded naked effect of each on IQ. In gen-
eral, for outcomes sensitive to both MeHg and 
PUFA, we would expect the β for MeHg to be 
negative and the β for PUFAs to be positive. 
The relationship among IQ, MeHg exposure, 
and PUFA intake (in the absence of interac-
tion) is described by a plane in three dimen-
sions (Figure 3). The tilt of the regression plane 
in three dimensions is determined by the inde-
pendent, unconfounded slopes (βs) of MeHg 
exposure and PUFA intake. In this example, 
as MeHg intake increases, PUFA intake would 
have to increase to maintain a mean IQ value 
in the population. Note also that in this hypo-
thetical example, there is a level of MeHg 
intake at which no increase in PUFA could 
result in an increase of x IQ points above the 
mean score. Although there has been no con-
sistent evidence of a MeHg–PUFA statistical 
interaction, such interactions may ultimately be 
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Figure 2. Odds ratios for nonfatal myocardial infarction as a function of mercury exposure (A) and DHA intake (B), each nonadjusted and adjusted for the negative 
confounding of the other. Data from Guallar et al. (2002).Methylmercury-PUFA risk–benefit
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interaction occurs, the relationship shown in 
Figure 3 becomes more complicated, but inter-
action can still be addressed in the approach we 
outline here. For the purposes of illustrating the 
principles of the approach, however, we assume 
the simple case of no statistical interaction.
This type of relationship allows us to 
predict the value for a dependent outcome 
variable, such as IQ, that would result from 
independent values of MeHg and PUFA. A 
given combination of MeHg exposure and 
PUFA intake can be chosen that reflects 
the characteristics of a particular consump-
tion pattern for a specific species of fish, for 
example, 8 oz of largemouth bass per week. 
Data on MeHg [U.S. Food and Drug 
Administration (FDA) 2009] and PUFA con-
centrations (Mahaffey 2004) in commonly 
consumed species of fish are available. The 
MeHg and PUFA intake rates combined with 
their respective unconfounded β values would 
uniquely express the balance of risk and ben-
efit that would result from that consumption 
pattern and species The same approach could 
also be applied to a diet that combines vari-
ous species of fish by summing the MeHg 
and PUFA intakes. Figure 4 assumes that 
unconfounded βs specific to the relationship 
of MeHg and PUFA intake to IQ perfor-
mance have been generated from the appro-
priate studies and that the combination of 
these fixed βs and variable levels of MeHg 
and PUFA intake deterministically influence 
IQ performance. Each of the solid lines repre-
sents a constant level of IQ performance (the 
population mean IQ and the mean ± x IQ 
points). Thus, each possible combination of 
MeHg and PUFA intake corresponds to a spe-
cific level of IQ performance. The dashed lines 
present three of these possible combinations, 
each corresponding to the MeHg and PUFA 
intake resulting from consumption of, for 
example, 8 oz/week of a hypothetical fish spe-
cies (or a specific fish diet). For fish 1, with a 
relatively low MeHg concentration and a rela-
tively high PUFA concentration, weekly intake 
of 8 oz/week would be expected to result, on 
average, in an increase in IQ score relative 
to the mean population score. On the other 
hand, for fish 3, with a relatively high MeHg 
concentration and a relatively low PUFA con-
centration, the same intake would, on average, 
result in a decrease in IQ score of equal mag-
nitude. An appropriate consumption advisory 
for fish 3 might caution against consumption 
of 8 oz/week. In theory, such data can be com-
bined in any combination to reflect the mix of 
MeHg and PUFA characteristics of any given 
species of fish or fish diet. The intake rate of 
that fish could then be adjusted to result in an 
overall benefit or, at least, the prevention of an 
overall negative outcome.
Critical Caveats
Even if we consider only neurodevelopmen-
tal outcomes, many apparently discrete end 
points have been identified that are sensitive to 
MeHg. If these end points are indeed discrete, 
then there does not appear to be an a priori 
reason to assume that a MeHg–PUFA regres-
sion relationship derived for one of these end 
points will hold for any other. Thus, a range 
of end points should be evaluated, and advi-
sories should be based on the end point most 
sensitive to MeHg risk. In addition, there is 
evidence that some end points respond nega-
tively to increasing MeHg exposure but do 
not respond positively to increasing PUFA 
exposure (Budtz-Jørgensen et al. 2007; Choi 
et al. 2008; Lederman et al. 2008). If such 
suggestions are confirmed, end points adversely 
associated with MeHg without being posi-
tively associated with PUFA would seem to be 
the most sensitive end points, and risk–benefit 
advisories for such end points would collapse 
to the original approach of risk-only adviso-
ries. The overall picture of the relevant end 
points and their relative sensitivities to MeHg 
risk and PUFA benefit will likely emerge from 
a review of multiple studies.
An additional caveat arises from Strain 
et al. (2008). When both MeHg and the 
omega-3 PUFAs are controlled in the model of 
the 9-month and 30-month physical develop-
ment index, the omega-6 PUFAs appear to 
have an adverse effect (negative β) similar 
to MeHg but opposite to the effect of the 
omega-3 PUFAs. Thus, even if we consider 
only risk–benefit balancing for MeHg and 
the PUFAs, it may be insufficient to merely 
balance the risks and benefits of MeHg and 
the omega-3 PUFAs. Future studies designed 
to generate the appropriate unconfounded 
data for MeHg and PUFAs should therefore 
include the omega-6 PUFAs in their design,
Other Risk–Benefit Advisory 
Approaches for MeHg/PUFAs
Ginsberg and Toal (2009) derived a quanti-
tative risk–benefit approach using empirical 
slopes of risk and benefit versus intake for 
myocardial infarction derived from Guallar 
et al. (2002) and a single neurodevelopmental 
end point, visual recognition memory score, 
derived from Oken et al. (2005). However, 
Oken et al. (2005) reported the rate of fish 
meals rather than PUFA per se, and the abil-
ity to appropriately control PUFA benefit 
for MeHg effects on that basis is not clear. 
In addition, as discussed above, reliance on 
the risk–benefit balance from a single neuro-
developmental end point may lead to con-
sumption advice that is not protective for 















Figure 3. Three-dimensional projection of a hypothetical relationship among IQ, MeHg intake, and PUFA 
intake with IQ regressed on MeHg and PUFA. The lines show constant values of IQ scores relative to vary-























Figure 4. An example of how the same weekly 
intake of different species of fish with different 
characteristic MeHg and PUFA concentrations 
would influence IQ scores given a hypothetical 
regression relationship among IQ, MeHg exposure, 
and PUFA intake (see the description of this figure 
in the text for a more detailed explanation). x desig-
nates a specific, but indeterminate value.  Stern and Korn
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approach presented by Ginsberg and Toal is 
consistent with the approach presented here.
Gochfeld and Burger (2005) conducted a 
careful search for cardiovascular and develop-
mental thresholds and asymptotes for fish 
consumption per se and compared these with 
regulatory guidelines for MeHg adverse effects 
[the U.S. EPA RfD (2001) and the Agency for 
Toxic Substances Disease Registry (ATSDR) 
minimal risk level (MRL) (ATSDR 1999)]. 
The apparent thresholds and benefit asymp-
totes were compared in order to derive curves 
that express overall risk and benefit as a func-
tion of grams per day of fish consumption for 
fish with assumed MeHg concentrations. As 
discussed above, these benefits data are likely 
to be confounded by the adverse effects of 
co-occurring MeHg. Furthermore, the regula-
tory guidelines for MeHg derived from studies 
that did not control for PUFA effects are likely 
confounded by PUFA benefits.
Steps Forward
To provide unconfounded independent risk 
and benefit data, future cohort studies of 
fish-consuming populations should include 
dietary-based estimates of MeHg and PUFA 
intake and/or biomarkers of PUFAs, omega-3 
and omega-6, and MeHg exposure. This may 
require additional work on PUFA pharmaco-
kinetic modeling. Intake estimates should be 
included in regression (or structural equation) 
models to produce adjusted estimates of ben-
efit and risk. If PUFA–MeHg interactions 
occur, nonlinear relationships among PUFA 
and MeHg intakes and outcomes will need to 
be addressed. This approach should be applied 
to studies of neurological development and to 
studies of cardiovascular effects. Particularly for 
neurodevelopmental outcomes, it will be neces-
sary to generate unconfounded risk and bene  fit 
relationships for multiple developmentally sig-
nificant outcomes to identify those that are 
most sensitive to MeHg risk and least subject 
to PUFA benefit. Particular attention should 
be given to identifying end points that may 
experience risk but no compensating benefit.
Conclusions
Evidence for the beneficial effects of PUFAs in 
fish for cardiovascular and developmental end 
points and for the subtle, subclinical adverse 
effects of MeHg has been accumulating for 
more than a decade. Initially, the tendency 
was to assume that either risk or benefit was 
the most important parameter when consider-
ing fish consumption advisories. There is now 
a growing recognition that the most useful fish 
consumption advisories need to simultane-
ously address both PUFA benefit and MeHg 
risk and that both are tightly linked through 
fish consumption. For at least some important 
end points, the risks and benefits are mutually 
confounding, and neither can be adequately 
understood in isolation. It appears that the 
only way to untangle this confounding is 
through statistical approaches that reveal the 
naked (unconfounded) risk and benefit coef-
ficients (βs) for each end point. Subsequent 
recombination of the risk and benefit coeffi-
cients can then describe the overall risk–  benefit 
profile of each species of fish for a given end 
point. However, close reading of the literature 
suggests that different end points have differ-
ent coefficients for risk and benefit and that 
some end points may be adversely affected by 
MeHg without experiencing beneficial effects 
of PUFA. This implies that there may be no 
such thing as an a priori representative end 
point that can be used arbitrarily to construct 
risk–benefit guidance, even given uncon-
founded coefficients for PUFA and MeHg. At 
least for neurodevelopment, it may be neces-
sary to generate PUFA and MeHg coefficients 
for each end point deemed to have indepen-
dent public health significance to identify the 
most risk-sensitive end point for use in con-
structing fish consumption advisories.
We encourage future researchers to gener-
ate data that relate both MeHg and PUFA 
intake to a range of end points in a way that 
allows the risks and benefits to be statistically 
disentangled and recombined to facilitate 
  generalizable consumption advice.
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